← Back to Clinical Trials
Recruiting NCT02432079

NCT02432079 Molecular Genetics of Heterotaxy and Related Congenital Heart Defects

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02432079
Status Recruiting
Phase
Sponsor Indiana University
Condition Heterotaxy Syndrome
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 2009-07
Primary Completion 2030-12

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 2009-07 with a primary completion date of 2030-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to obtain specimens and data from individuals and their families with heterotaxy and related congenital heart defects in order to clarify the molecular genetics of this disorder. The knowledge gained from the analysis of this information will provide the basis for future genetic counseling as well as contribute to knowledge about the biology of normal and abnormal development of left-right anatomic asymmetry.

Eligibility Criteria

Inclusion Criteria: * Subjects with heterotaxy and related congenital heart defects * Family members of subjects with heterotaxy and related congenital heart defects Exclusion Criteria: * Subjects without heterotaxy and related congenital heart defects * Family members of subjects without heterotaxy and related congenital heart defects

Contact & Investigator

Central Contact

Sarah K. Murphy, MPH

✉ bankssk@iu.edu

📞 317-278-3026

Principal Investigator

Stephanie M. Ware, MD, PhD

PRINCIPAL INVESTIGATOR

Indiana University

Frequently Asked Questions

Who can join the NCT02432079 clinical trial?

This trial is open to participants of all sexes, studying Heterotaxy Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT02432079 currently recruiting?

Yes, NCT02432079 is actively recruiting participants. Contact the research team at bankssk@iu.edu for enrollment information.

Where is the NCT02432079 trial being conducted?

This trial is being conducted at Indianapolis, United States.

Who is sponsoring the NCT02432079 clinical trial?

NCT02432079 is sponsored by Indiana University. The principal investigator is Stephanie M. Ware, MD, PhD at Indiana University. The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology